Literature DB >> 25656478

Carbamazepine and oxcarbazepine, but not eslicarbazepine, enhance excitatory synaptic transmission onto hippocampal CA1 pyramidal cells through an antagonist action at adenosine A1 receptors.

Sam A Booker1, Nuno Pires2, Stuart Cobb3, Patrício Soares-da-Silva4, Imre Vida5.   

Abstract

This study assessed the anticonvulsant and seizure generation effects of carbamazepine (CBZ), oxcarbazepine (OXC) and eslicarbazepine (S-Lic) in wild-type mice. Electrophysiological recordings were made to discriminate potential cellular and synaptic mechanisms underlying anti- and pro-epileptic actions. The anticonvulsant and pro-convulsant effects were evaluated in the MES, the 6-Hz and the Irwin tests. Whole-cell patch-clamp recordings were used to investigate the effects on fast excitatory and inhibitory synaptic transmission in hippocampal area CA1. The safety window for CBZ, OXC and eslicarbazepine (ED50 value against the MES test and the dose that produces grade 5 convulsions in all mice), was 6.3, 6.0 and 12.5, respectively. At high concentrations the three drugs reduced synaptic transmission. CBZ and OXC enhanced excitatory postsynaptic currents (EPSCs) at low, therapeutically-relevant concentrations. These effects were associated with no change in inhibitory postsynaptic currents (IPSCs) resulting in altered balance between excitation and inhibition. S-Lic had no effect on EPSC or IPSC amplitudes over the same concentration range. The CBZ mediated enhancement of EPSCs was blocked by DPCPX, a selective antagonist, and occluded by CCPA, a selective agonist of the adenosine A1 receptor. Furthermore, reduction of endogenous adenosine by application of the enzyme adenosine deaminase also abolished the CBZ- and OXC-induced increase of EPSCs, indicating that the two drugs act as antagonists at native adenosine receptors. In conclusion, CBZ and OXC possess pro-epileptic actions at clinically-relevant concentrations through the enhancement of excitatory synaptic transmission. S-Lic by comparison has no such effect on synaptic transmission, explaining its lack of seizure exacerbation.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  A(1) adenosine receptor; Carbamazepine; Epilepsy; Eslicarbazepine; Oxcarbazepine; Synaptic transmission

Mesh:

Substances:

Year:  2015        PMID: 25656478     DOI: 10.1016/j.neuropharm.2015.01.019

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  6 in total

1.  The Influence of Solid Microneedles on the Transdermal Delivery of Selected Antiepileptic Drugs.

Authors:  Julia Nguyen; Kevin B Ita; Matthew J Morra; Inna E Popova
Journal:  Pharmaceutics       Date:  2016-11-15       Impact factor: 6.321

2.  Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies.

Authors:  Christian Elger; Mathias Koepp; Eugen Trinka; Vicente Villanueva; João Chaves; Elinor Ben-Menachen; Pedro A Kowacs; António Gil-Nagel; Joana Moreira; Helena Gama; José-Francisco Rocha; Patrício Soares-da-Silva
Journal:  CNS Neurosci Ther       Date:  2017-10-13       Impact factor: 5.243

Review 3.  Eslicarbazepine acetate in the treatment of adults with partial-onset epilepsy: an evidence-based review of efficacy, safety and place in therapy.

Authors:  Simona Lattanzi; Francesco Brigo; Claudia Cagnetti; Alberto Verrotti; Gaetano Zaccara; Mauro Silvestrini
Journal:  Core Evid       Date:  2018-03-08

Review 4.  Excitatory and inhibitory synaptic dysfunction in mania: an emerging hypothesis from animal model studies.

Authors:  Yeunkum Lee; Yinhua Zhang; Shinhyun Kim; Kihoon Han
Journal:  Exp Mol Med       Date:  2018-04-09       Impact factor: 8.718

5.  Long-term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open-label extension study.

Authors:  Eugen Trinka; Rodrigo Rocamora; João Chaves; Joana Moreira; Fábio Ikedo; Patrício Soares-da-Silva
Journal:  Epilepsia       Date:  2020-09-17       Impact factor: 5.864

6.  Treating GNAO1 mutation-related severe movement disorders with oxcarbazepine: a case report.

Authors:  Weihao Ling; Danping Huang; Fan Yang; Zuozhen Yang; Min Liu; Qiujiao Zhu; Jing Huang; Rui Zhou; Xuqin Chen
Journal:  Transl Pediatr       Date:  2022-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.